# A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

> **NCT07287098** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 600 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Imlunestrant
- **DRUG:** Goserelin
- **DRUG:** Tamoxifen 20 mg

## Key facts

- **NCT ID:** NCT07287098
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-01
- **Final completion:** 2029-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07287098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07287098, "A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07287098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*